Why we may be more like our pets than we think Why we may be more like our pets than we think The bond between owners and their pets goes beyond physical resemblance as we are increasingly facing similar health problems.
2019 performance 2019 performance Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
Partnership for new liver disease treatments with Ribo Partnership for new liver disease treatments with Ribo Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
Boehringer acquires T3 Pharma Boehringer acquires T3 Pharma Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Large Scale Cell Culture Facility | Bioxcellence | Boehringer Ingelheim Large Scale Cell Culture Facility | Bioxcellence | Boehringer Ingelheim Tour our Large Scale Cell Culture Facility in Vienna, Austria, advancing biopharmaceutical production with cutting-edge cell culture technology.
Solid Fundations | Bioxcellence | Boehringer Ingelheim Solid Fundations | Bioxcellence | Boehringer Ingelheim Discover BioXcellence's innovative biopharmaceutical contract manufacturing services, built on a proven track record & solid foundation. Explore now!
Over 100 billion birds vaccinated with VAXXITEK Over 100 billion birds vaccinated with VAXXITEK Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.
Non-small cell lung cancer Non-small cell lung cancer Discover more about non-small cell lung cancer, including its symptoms and treatment options.
New treatment for chronic kidney disease approved in the EU New treatment for chronic kidney disease approved in the EU The European Commission (EC) has approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease
Boehringer Ingelheim advances SIRP immune-oncology program Boehringer Ingelheim advances SIRP immune-oncology program Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
Introducing CIAS Introducing CIAS Schizophrenia affects 1 in 100, yet the condition can be misunderstood due to some symptoms being overlooked, such as cognitive impairment
Niha Agarwalla Niha Agarwalla My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
bix_facilitates_global_partnerships bix_facilitates_global_partnerships BI X focuses on partnerships to speed up the development of digital healthcare solutions
Boehringer Ingelheim supports collaboration and knowledge sharing in the livestock industry Boehringer Ingelheim supports collaboration and knowledge sharing in the livestock industry Boehringer Ingelheim demonstrates its commitment to farm animal well-being by organising its 11th Expert Forum on Farm Animal Well-Being
digital_leader_award_2020 digital_leader_award_2020 Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award
Boehringer Ingelheim acquires a stake in SoundTalks Boehringer Ingelheim acquires a stake in SoundTalks Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme
Boehringer Ingelheim partners with GNA Biosolutions Boehringer Ingelheim partners with GNA Biosolutions Boehringer Ingelheim partners with GNA Biosolutions to develop African swine fever diagnostic test.
What we do What we do Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
“Rapid progress towards clinical candidates” “Rapid progress towards clinical candidates” Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
FOYA_Shanghai FOYA_Shanghai Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”
Digital Transformation Within Our Global IT Digital Transformation Within Our Global IT Technology is at the heart of our strategy.
Boehringer Olaf Scholz break ground for innovation center Boehringer Olaf Scholz break ground for innovation center Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center